Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report

Revista Brasileira de Psiquiatria

Volumn 37, Issue 1, 2015, Pages 13-20

  de Osório, Flávia L ^b   Sanches, Rafael F ^a,c   Macedo, Ligia R ^a   dos Santos, Rafael G ^a   Maia De Oliveira, João P ^d   Wichert Ana, Lauro ^a   de Araujo, Draulio B ^d   Riba, Jordi ^c,e,f   Crippa, José A ^a,b   Hallak, Jaime E ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Science and Technology Institute for Translational Medicine (INCT TM)   (Brazil)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Dimethyltryptamine; Harmine; Monoamine oxidase inhibitors; Psychedelic agents; Therapeutic use

Indexed keywords

AYAHUASCA; HARMALINE; HARMINE; N,N DIMETHYLTRYPTAMINE; PLANT MEDICINAL PRODUCT; PSYCHEDELIC AGENT; TETRAHYDROHARMINE; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT;

ADULT; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHROMATOGRAPHY; CLINICAL ARTICLE; CONFUSION; DEPRESSED MOOD; DISEASE SEVERITY; DYSPHORIA; FEMALE; GUILT; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPOMANIA; IRRITABILITY; MAJOR DEPRESSION; MALE; MANIA; MASS FRAGMENTOGRAPHY; MENTAL DISEASE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; PESSIMISTIC THINKING; PSYCHOMOTOR RETARDATION; RECURRENT DISEASE; SADNESS; SINGLE DRUG DOSE; SUICIDAL IDEATION; TRANQUILIZING ACTIVITY; VOMITING; YOUNG MANIA RATING SCALE; ANALYSIS OF VARIANCE; BANISTERIOPSIS; CHEMISTRY; DEPRESSIVE DISORDER; PHYTOTHERAPY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BANISTERIOPSIS; BRIEF PSYCHIATRIC RATING SCALE; DEPRESSIVE DISORDER; FEMALE; HALLUCINOGENS; HARMINE; HUMANS; MALE; MIDDLE AGED; N,N-DIMETHYLTRYPTAMINE; PHYTOTHERAPY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84933067222     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2014-1496     Document Type: Article

References (40)

1. Ebmeier KP, Donaghey C, Steele D. Recent developments and current controversies in depression. Lancet. 2006;367:153-67.
2. Andrade LH, Wang YP, Andreoni S, Silveira CM, Alexandrino-Silva C, Siu ER, et al. Mental disorders in megacities: findings from the São Paulo megacity mental health survey, Brazil. PLoS One. 2012;7:e31879.
3. Pacher P, Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem. 2004;11:925-43.
4. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry. 2013;47:710-27.
5. Salvadore G, Singh JB. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther. 2013; 19:428-36.
6. Schultes RE, Hofmann A. Plants of the gods: their sacred, healing, and hallucinogenic powers. Rochester: Healing Arts Press; 1992.
7. Labate BC, Rose IS, dos Santos RG. Ayahuasca religions: a comprehensive bibliography and critical essays. Santa Cruz: Multidisciplinary Association for Psychedelic Studies; 2009.
8. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, et al. Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology (Berl). 2001;154:85-95.
9. Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306:73-83.
10. dos Santos RG, Valle M, Bouso JC, Nomdedéu JF, Rodríguez- Espinosa J, McIlhenny EH, et al. Autonomic, neuroendocrine and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol. 2011;31:717-26.
11. dos Santos RG, Grasa E, Valle M, Ballester MR, Bouso JC, Nomdedéu JF, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl). 2012;219:1039-53.
12. Riba J, Romero S, Grasa E, Mena E, Carrió I, Barbanoj MJ. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006;186: 93-8.
13. Barbosa PC, Mizumoto S, Bogenschutz MP, Strassman RJ. Health status of ayahuasca users. Drug Test Anal. 2012;4:601-9.
14. Bouso JC, Gonzá lez D, Fondevila S, Cutchet M, Fernández X, Ribeiro Barbosa PC, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PLoS One. 2012;7:e42421.
15. dos Santos RG. Safety and side effects of ayahuasca in humans – An overview focusing on developmental toxicology. J Psychoactive Drugs. 2013;45:68-78.
16. Hilber P, Chapillon P. Effects of harmaline on anxiety-related behavior in mice. Physiol Behav. 2005;86:164-7.
17. Farzin D, Mansouri N. Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test. Eur Neuropsychopharmacol. 2006;16:324-8.
18. Lima LM, Ferreira MS, Á vila AA, Perazzo FF, Schneedorf JM, Hinsberger A, et al. Ayahuasca central nervous system effects: behavioral study. A¨ rztezeitschrift Naturheilverfahren. 2006;47:476-80.
19. Fortunato JJ, Réus GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F, et al. Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1425-30.
20. Wu C, Jiang XL, Shen HW, Yu AM. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol. 2009;78:617-24.
21. Fortunato JJ, Réus GZ, Kirsch TR, Stringari RB, Fries GR, Kapczinski F, et al. Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in the rat hippocampus. J Neural Transm. 2010;117:1131-7.
22. Fortunato JJ, Réus GZ, Kirsch TR, Stringari RB, Fries GR, Kapczinski F, et al. Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res Bull. 2010;81:491-6.
23. Réus GZ, Stringari RB, de Souza B, Petronilho F, Dal-Pizzol F, Hallak JE, et al. Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid Med Cell Longev. 2010;3:325-31.
24. Réus GZ, Stringari RB, Gonçalves CL, Scaini G, Carvalho-Silva M, Jeremias GC, et al. Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain. Depress Res Treat. 2012;2012:987397.
25. dos Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V, Cruz AP. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007;112:507-13.
26. Palhano-Fontes F, Alchieri JC, Oliveira JPM, Soares BL, Hallak JEC, Galvao-Coelho N, et al. The therapeutic potentials of ayahuasca in the treatment of depression. In: Labate BC, Cavnar C, editors. The therapeutic use of ayahuasca. Berlin/Heidelberg: Springer-Verlag; 2014. p 23-39.
27. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV Axis I disorders, clinician version (SCID-CV). Washington: American Psychiatric; 1996.
28. Del-Ben CM, Vilela JAA, Crippa JAS, Hallak JEC, Labate CM, Zuardi AW. Confiabilidade da entrevista clínica estruturada para o DSM-IV - versaäo clínica’’ traduzida para o portugueˆ s. Rev Bras Psiquiatr. 2001;23:156-9.
29. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
30. Crippa JA, Sanches RF, Hallak JE, Loureiro SR, Zuardi AW. Factor structure of Bech’s version of the Brief Psychiatric Rating Scale in Brazilian patients. Braz J Med Biol Res. 2002;35:1209-13.
31. Young RC, Biggs JT, Ziegler E, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. British J Psychiatry. 1978;133:429-35.
32. Vilela JA, Crippa JA, Del-Ben CM, Loureiro SR. Reliability and validity of a Portuguese version of the Young Mania Rating Scale. Braz J Med Biol Res. 2005;38:1429-39.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
34. Moreno RA, Moreno DH. Escalas de depressao de Montgomery & Asberg (MADRS) e de Hamilton (HAM-D). Rev Psiquiatr Clin. 1998;25:262-72.
35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
36. Buckholtz NS, Boggan WO. Monoamine oxidase inhibition in brain and liver produced by b-carbolines: structure-activity relationships and substrate specificity. Biochem Pharmacol. 1977;26:1991-6.
37. Buckholtz NS, Boggan WO. Inhibition by b-carbolines of monoamine uptake into a synaptosomal preparation: structure-activity relationships. Life Sci. 1977;20:2093-9.
38. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25:215-21.
39. Riba J, Barbanoj MJ. Bringing ayahuasca to the clinical research laboratory. J Psychoactive Drugs. 2005;37:219-30.
40. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22:603-20.